Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Update

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) was the recipient of a large drop in short interest in the month of June. As of June 30th, there was short interest totaling 7,148 shares, a drop of 65.8% from the June 15th total of 20,871 shares. Approximately 0.2% of the company’s shares are short sold. Based on an average daily volume of 29,227 shares, the short-interest ratio is currently 0.2 days.

Kiora Pharmaceuticals Stock Up 0.8%

NASDAQ:KPRX traded up $0.02 on Tuesday, reaching $2.48. 22,135 shares of the company’s stock were exchanged, compared to its average volume of 256,284. The firm has a market capitalization of $10.99 million, a price-to-earnings ratio of -0.92 and a beta of -0.40. Kiora Pharmaceuticals has a 52-week low of $1.76 and a 52-week high of $3.29. The business has a fifty day moving average of $2.58 and a 200-day moving average of $2.31.

Kiora Pharmaceuticals (NASDAQ:KPRX) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.58) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.58).

Analyst Ratings Changes

Separately, Weiss Ratings downgraded shares of Kiora Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, June 26th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $10.00.

Institutional Investors Weigh In On Kiora Pharmaceuticals

A number of large investors have recently modified their holdings of the company. Alyeska Investment Group L.P. acquired a new position in shares of Kiora Pharmaceuticals during the fourth quarter worth $152,000. DRW Securities LLC increased its holdings in Kiora Pharmaceuticals by 199.2% in the fourth quarter. DRW Securities LLC now owns 110,282 shares of the company’s stock valued at $217,000 after buying an additional 73,417 shares during the last quarter. Citadel Advisors LLC acquired a new stake in Kiora Pharmaceuticals in the third quarter valued at $125,000. Two Sigma Investments LP purchased a new position in Kiora Pharmaceuticals in the third quarter valued at approximately $33,000. Finally, Renaissance Technologies LLC raised its holdings in Kiora Pharmaceuticals by 71.0% during the fourth quarter. Renaissance Technologies LLC now owns 21,200 shares of the company’s stock worth $42,000 after purchasing an additional 8,800 shares in the last quarter. 76.97% of the stock is owned by hedge funds and other institutional investors.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.

The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders.